Tue, Apr 29, 10:53 AM (20 days ago)
**Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Financial Summary:** **Revenue:** $3.029 billion, down 3.7% year-over-year (YoY) from $3.145 billion in Q1 2024. **Net Income:** $808.7 million, up 12.8% YoY from $722.0 million in Q1 2024. **Earnings per Share (EPS):** $7.27 diluted, up 16.6% YoY from $6.27 in Q1 2024. **Key Products:** - **EYLEA HD:** $306.8 million, up 53.4% YoY from $200.0 million. - **EYLEA:** $736.0 million, down 38.7% YoY from $1.202 billion. - **Libtayo:** $285.1 million, up 7.6% YoY from $263.9 million. - **Praluent:** $56.8 million, down 21.9% YoY from $70.0 million. - **Evkeeza:** $30.9 million, up 26.2% YoY from $24.8 million. **Operating Expenses:** $2.437 billion, up 1.8% YoY from $2.394 billion. **Research & Development (R&D):** $1.327 billion, up 6.3% YoY from $1.248 billion. **Selling, General, & Administrative (SG&A):** $633.0 million, down 13.0% YoY from $729.0 million. **Cash Flow from Operations:** $1.045 billion, down 30.2% YoY from $1.513 billion. **Cash Flow from Investing:** $647.5 million, up 144.7% YoY from $(1.687) billion. **Cash Flow from Financing:** $(1.089) billion, down 113.6% YoY from $47.1 million. **Cash & Cash Equivalents:** $3.093 billion, up 18.4% YoY from $2.609 billion. **Debt:** $1.985 billion, flat YoY. **Share Repurchases:** $1.052 billion in Q1 2025, up from $298.0 million in Q1 2024. **Dividends:** Declared a quarterly cash dividend of $0.88 per share on Common Stock and Class A Stock. **Outlook:** - **Revenue Guidance:** No specific guidance provided. - **EPS Guidance:** No specific guidance provided. - **R&D Guidance:** Expects to incur $850 million to $950 million in capital expenditures for the full year of 2025. **Trends & Uncertainties:** - **EYLEA HD** saw significant growth, while **EYLEA** faced competitive pressures. - **Libtayo** and **Evkeeza** showed positive trends. - **Praluent** experienced a decline in sales. - **Operating expenses** increased slightly, driven by higher R&D investments. - **Cash flow from operations** decreased due to higher investments and share repurchases. - **Cash flow from investing** improved significantly due to better investment returns. - **Cash flow from financing** turned negative due to substantial share repurchases. **Future Operations Impact:** - **Continued investment** in R&D and capital expenditures. - **Focus on EYLEA HD** and other growth products. - **Share repurchases** and dividends to enhance shareholder value. - **Uncertainties** include competitive pressures, regulatory approvals, and market conditions.